risperidone has been researched along with Atherosclerotic Parkinsonism in 20 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia." | 9.09 | Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. ( Adler, CM; Breier, AF; Clifton, A; Elman, I; Lafargue, RT; Malhotra, AK; Pickar, D; Pinals, DA; Su, TP, 1999) |
| "Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia." | 5.09 | Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. ( Adler, CM; Breier, AF; Clifton, A; Elman, I; Lafargue, RT; Malhotra, AK; Pickar, D; Pinals, DA; Su, TP, 1999) |
| "We compared the incidence of parkinsonism after new treatment with risperidone, olanzapine, or quetiapine in patients with dementia and examined the effects of dose and sex on the risk of parkinsonism." | 3.78 | Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex. ( Anderson, GM; Fischer, HD; Herrmann, N; Marras, C; Rochon, PA; Wang, X, 2012) |
| " We used the Generalized Propensity Score method to evaluate the dose-response risk of Parkinsonism associated with SGAs." | 1.56 | Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study. ( Chyou, TY; Nishtala, PS; Nishtala, R, 2020) |
| " EPS were assessed at baseline and 4, 8, and 12 weeks after naturalistic SGA initiation for schizophrenia, mood, disruptive behavior, and autism spectrum disorders using the Simpson-Angus Scale (SAS), Barnes Akathisia Scale, Abnormal Involuntary Movement Scale (AIMS), and Treatment Emergent Side Effect Scale." | 1.42 | Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. ( Al-Jadiri, A; Azzo, S; Carbon, M; Correll, CU; Kane, JM; Kapoor, S; Saito, E; Sarkaria, T; Sheridan, E, 2015) |
| "Risperidone was associated with higher increases in DyskinesiaS compared with quetiapine (P < 0." | 1.42 | Neurological Adverse Effects of Antipsychotics in Children and Adolescents. ( Alda, JA; Andrés Nestares, P; Arango, C; Baeza, I; Cantarero, CM; Castro-Fornieles, J; de la Serna, E; Garcia-Amador, M; Merchán-Naranjo, J; Moreno, C; Muñoz, D; Tapia, C, 2015) |
| "Risperidone (4 mg/day) was added to her drug regimen and after increasing the dosage to 6 mg/day, she began to exhibit retrocollis." | 1.31 | Tardive dystonia provoked by concomitantly administered risperidone. ( Hori, M; Hori, T; Kawanishi, Y; Shiraishi, H; Suzuki, T; Tachikawa, H, 2000) |
| "Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors." | 1.30 | Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. ( Heinz, A; Knable, MB; Raedler, T; Weinberger, DR, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (40.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chyou, TY | 1 |
| Nishtala, R | 1 |
| Nishtala, PS | 1 |
| Bolu, A | 1 |
| Garip, B | 1 |
| Öznur, T | 1 |
| Uzun, Ö | 1 |
| Carbon, M | 1 |
| Kapoor, S | 1 |
| Sheridan, E | 1 |
| Al-Jadiri, A | 1 |
| Azzo, S | 1 |
| Sarkaria, T | 1 |
| Kane, JM | 1 |
| Saito, E | 1 |
| Correll, CU | 1 |
| Garcia-Amador, M | 1 |
| Merchán-Naranjo, J | 1 |
| Tapia, C | 1 |
| Moreno, C | 1 |
| Castro-Fornieles, J | 1 |
| Baeza, I | 1 |
| de la Serna, E | 1 |
| Alda, JA | 1 |
| Muñoz, D | 1 |
| Andrés Nestares, P | 1 |
| Cantarero, CM | 1 |
| Arango, C | 1 |
| Lamkin, S | 1 |
| Buhl, D | 1 |
| Karanec, K | 1 |
| McWilliams-Dunnigan, L | 1 |
| Alshekhlee, A | 1 |
| Baez, MA | 1 |
| Avery, J | 1 |
| Marras, C | 1 |
| Herrmann, N | 1 |
| Anderson, GM | 1 |
| Fischer, HD | 1 |
| Wang, X | 1 |
| Rochon, PA | 1 |
| Wöhrle, JC | 1 |
| Weigel, R | 1 |
| Grips, E | 1 |
| Blahak, C | 1 |
| Capelle, HH | 1 |
| Krauss, JK | 1 |
| Mateos, JJ | 1 |
| Lomeña, F | 1 |
| Parellada, E | 1 |
| Mireia, F | 1 |
| Fernandez-Egea, E | 1 |
| Pavia, J | 1 |
| Prats, A | 1 |
| Pons, F | 1 |
| Bernardo, M | 1 |
| Høyberg, OJ | 1 |
| Fensbo, C | 1 |
| Remvig, J | 1 |
| Lingjaerde, O | 1 |
| Sloth-Nielsen, M | 1 |
| Salvesen, I | 1 |
| Rich, SS | 1 |
| Friedman, JH | 1 |
| Ott, BR | 1 |
| Maany, I | 1 |
| Gwinn, KA | 1 |
| Caviness, JN | 1 |
| Knable, MB | 1 |
| Heinz, A | 1 |
| Raedler, T | 1 |
| Weinberger, DR | 1 |
| Breier, AF | 1 |
| Malhotra, AK | 1 |
| Su, TP | 1 |
| Pinals, DA | 1 |
| Elman, I | 1 |
| Adler, CM | 1 |
| Lafargue, RT | 1 |
| Clifton, A | 1 |
| Pickar, D | 1 |
| Roberts, MD | 1 |
| Tachikawa, H | 1 |
| Suzuki, T | 1 |
| Kawanishi, Y | 1 |
| Hori, M | 1 |
| Hori, T | 1 |
| Shiraishi, H | 1 |
| Wirshing, WC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| I-123 Iodobenzamide (IBZM) SPECT Studies of D2 Receptor Distribution and Function in Patients With Schizophrenia and Normal Volunteers[NCT00001320] | 265 participants | Observational | 1991-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for risperidone and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
Movement disorders associated with neuroleptic treatment.
Topics: Age Factors; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; | 2001 |
3 trials available for risperidone and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.
Topics: Adult; Antipsychotic Agents; Caudate Nucleus; Dopamine Plasma Membrane Transport Proteins; Down-Regu | 2007 |
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Denmark; Double-Blind Method; Female; Humans; Isox | 1993 |
Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Clozapine; Double-Blind Method | 1999 |
15 other studies available for risperidone and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Databases, Factual; Female; Humans; Inci | 2020 |
Case of risperidone-induced tardive parkinsonism.
Topics: Adult; Antipsychotic Agents; Humans; Male; Parkinson Disease, Secondary; Risperidone; Schizophrenia; | 2019 |
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dru | 2015 |
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Drug-Related Side Effect | 2015 |
Extrapyramidal side effects: could you identify them in the emergency department?
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dopamine Antagonists; Dyskinesi | 2009 |
Retropulsion and back bruises in drug-induced parkinsonism.
Topics: Accidental Falls; Aged; Antipsychotic Agents; Back; Biomechanical Phenomena; Bipolar Disorder; Contu | 2010 |
Improvement in drug-induced parkinsonism with electroconvulsive therapy.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Depressive Disorder, Major; Electroconvulsive Ther | 2011 |
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Dementia; Dibenzothi | 2012 |
Risperidone-responsive segmental dystonia and pallidal deep brain stimulation.
Topics: Aged; Antidepressive Agents; Combined Modality Therapy; Cyclohexanols; Depression; Dopamine Antagoni | 2003 |
Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.
Topics: Aged; Antiparkinson Agents; Clozapine; Dyskinesia, Drug-Induced; Humans; Male; Parkinson Disease; Pa | 1995 |
Adverse interaction of tacrine and haloperidol.
Topics: Aged; Dementia; Drug Interactions; Drug Therapy, Combination; Female; Haloperidol; Humans; Parkinson | 1996 |
Risperidone-induced tardive dyskinesia and parkinsonism.
Topics: Aged; Antipsychotic Agents; Bipolar Disorder; Dyskinesia, Drug-Induced; Humans; Male; Neurologic Exa | 1997 |
Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Brain Mapping; Dopamine Anta | 1997 |
Risperdal and parkinsonian tremor.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 1999 |
Tardive dystonia provoked by concomitantly administered risperidone.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Drug Therapy, Combination; Dyskinesia, Drug-Induce | 2000 |